GSK
GSK plc
There isn't enough reported data to score GSK yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GSK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Healthy |
GSK's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GSK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.7x | $16.03 | -68% |
| Fair | 14x | $25.09 | -50% |
| Current | 14x | $50.64 | — |
| Expensive | 16x | $29.98 | -41% |
Historical ranges are pointers, not guarantees.
GSK's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
GSK has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $1.85 | +123% |
| Q4 2024 | $0.83 | -48% |
| Q4 2023 | $1.59 | -67% |
| Q4 2022 | $4.87 | +238% |
| Q4 2021 | $1.44 | -24% |
| Q4 2020 | $1.90 | +23% |
| Q4 2019 | $1.54 | +27% |
| Q4 2018 | $1.21 | +133% |
GSK has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $43.5B | +4.1% |
| Q4 2024 | $41.7B | +3.5% |
| Q4 2023 | $40.3B | +3.4% |
| Q4 2022 | $39B | -14% |
| Q4 2021 | $45.4B | 0% |
| Q4 2020 | $45.4B | +1% |
| Q4 2019 | $44.9B | +9.5% |
| Q4 2018 | $41B | +2.1% |
GSK's revenue is shrinking: $43.5B last quarter, down 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 24% | +6.1 points |
| Q4 2024 | 13% | -10 points |
| Q4 2023 | 22% | +1.6 points |
| Q4 2022 | 22% | +4.2 points |
| Q4 2021 | 18% | +4.6 points |
| Q4 2020 | 23% | +15 points |
| Q4 2019 | 21% | +1.7 points |
| Q4 2018 | 18% | N/A |
GSK's operating margin was 24% last quarter, up 6.1 points from the same quarter a year ago, near the top of its range since 2016.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GSK in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $8.5B | +24% |
| Q4 2024 | $6.9B | -5.5% |
| Q4 2023 | $7.3B | -13% |
| Q4 2022 | $8.3B | -7.7% |
| Q4 2021 | $9B | -6% |
| Q4 2020 | $9.6B | +6.8% |
| Q4 2019 | $9B | -4.5% |
| Q4 2018 | $9.4B | +32% |
GSK's free cash flow has been positive every quarter since mid-2016: $30.9B over the past year, down 16% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
GSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -25M shares |
| 1 year | +1.6% | +65M shares |
| 3 years | +110% | +2.2B shares |
GSK has 4.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $1.8B |
| Q4 2016 | $5.3M |
| Q3 2016 | $16M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GSK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 1.5x | Healthy |
| Q4 2024 | 2.0x | Moderate |
| Q4 2023 | 1.8x | Healthy |
| Q4 2022 | 2.2x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q4 2020 | 2.1x | Moderate |
| Q4 2019 | 3.2x | Elevated |
| Q4 2018 | 3.1x | Elevated |
GSK's net debt is about 1.5 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over GSK on leverage, with a lower net debt burden relative to earnings.
GSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.6 | Neutral |
| Stochastic | 55.5 | Neutral |
GSK's weekly RSI is 51 (neutral) and its Stochastic is 56 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GSK PE vs Healthcare Sector
| Metric | GSK | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 47% below |
| PE % | 53 | 29 | 24 pts above |
GSK is trading at 14x earnings, a 47% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $49.2 | 2.9% above |
| 20 week MA | $50.4 | 0.4% above |
| 50 week MA | $51.9 | 2.4% below |
| 100 week MA | $45.5 | 11% above |
| 200 week MA | $41.7 | 21% above |
GSK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.3 | $36.1 | -24% |
| 2021 | $36.1 | $43.8 | +21% |
| 2022 | $43.8 | $35.2 | -20% |
| 2023 | $35.2 | $37.1 | +5.2% |
| 2024 | $37.1 | $34.1 | -8% |
| 2025 | $34.1 | $49.1 | +44% |
| 2026 YTD | $49.1 | $50.6 | +3.2% |
GSK has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.